Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Orsay – page 24

3 415 clinical trials in Orsay, France across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Orsay at a glance
3 415
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

3 415 trials in Orsay

Open in trial search

Neoplasm

Recruiting

Telisotuzumab Adizutecan for Locally Advanced or Metastatic Solid Tumors with MET Amplification in Patients 12 Years and Older

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Telisotuzumab adizutecan
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Neoplasm

Recruiting

EIK1005 Alone and with Pembrolizumab for Advanced Solid Tumors in Patients with MSI-H or dMMR Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:EIK1005 sodium
  • Sponsor:Eikon Therapeutics Inc.

Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

QTX-2101 and Arsenic Trioxide in Adult Patients With Acute Promyelocytic Leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Arsenic Trioxide
  • Sponsor:Quetzal Therapeutics LLC

Open-Label Extension Study of ATH434-DP2 in Patients with Multiple System Atrophy

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:PBT-434 MESYLATE
  • Sponsor:Alterity Therapeutics Limited

Obrixtamig, Carboplatin, and Etoposide for First-Line Treatment of Advanced Extrapulmonary Neuroendocrine Carcinoma in DLL3-Positive Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Boehringer Ingelheim Espana S.A.

Obesity

Recruiting

RO7795068 for Weight Loss in Adults With Obesity or Overweight and Type 2 Diabetes

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Enicepatide
  • Sponsor:F. Hoffmann-La Roche AG

Vasopressin Versus Norepinephrine for Patients with Chronic Thromboembolic Pulmonary Hypertension After Pulmonary Endarterectomy Surgery

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Argipressin
  • Sponsor:Fondation Hopital Saint Joseph

A Study of BI 764532, Atezolizumab, Carboplatin, and Etoposide in Patients With Extensive-Stage Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Boehringer Ingelheim Espana S.A.

Phase 3 Study of LY4170156 (Sofetabart Mipitecan) with drug combination in platinum‑resistant and platinum‑sensitive ovarian cancer patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Eli Lilly & Co.

BMN 333 Versus Vosoritide in Children With Achondroplasia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:BMN 333
  • Sponsor:Biomarin Pharmaceutical Inc.

Cenegermin Eye Drops for Persistent Corneal Epithelial Defect in Patients with Persistent Corneal Epithelial Defect

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cenegermin
  • Sponsor:Dompe' Farmaceutici S.p.A.

Other cities in France

The busiest research cities in the country

All 376 cities in France

Clinical research in Orsay

What the registry says about research in the country

01 Neurological Studies

Advanced research focusing on neurological disorders including innovative imaging studies for epilepsy, multiple sclerosis, and Huntington's disease. These trials utilize cutting-edge PET-MRI technology to better understand disease progression and treatment effectiveness.

  • Drug-resistant epilepsy imaging
  • Multiple sclerosis inflammation markers
  • Huntington's disease biomarkers

Research aims to improve diagnostic accuracy and treatment planning through advanced imaging techniques.

02 Psychiatric & Mental Health

Innovative studies exploring treatments for mental health conditions, with a focus on early psychosis and severe depression. Trials evaluate novel therapeutic approaches combining medication and digital interventions.

  • Early psychosis treatment
  • Ketamine therapy for depression
  • Personalized care approaches

Research emphasizes personalized treatment strategies and innovative therapeutic combinations.

03 Critical Care Medicine

Studies addressing critical care challenges including septic shock management and specialized treatments for severe medical conditions. Focus on improving patient outcomes in intensive care settings.

  • Septic shock delirium prevention
  • Severe hyponatremia management
  • Ventilator-associated pneumonia

Trials aim to enhance treatment protocols in critical care scenarios.

04 Oncology & Imaging

Advanced research in cancer treatment and diagnostic imaging, particularly focusing on colorectal cancer and CNS lymphoma. Studies utilize innovative imaging techniques for better disease characterization.

  • Colorectal cancer therapy
  • CNS lymphoma imaging
  • PET/MR imaging applications

Research combines cutting-edge imaging with targeted therapeutic approaches.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.